Sponsor content
326 result(s) found, displaying 41 to 50
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LOKELMA sodium zirconium cyclosilicate hydrate 5 g powder for oral suspension sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LOKELMA sodium zirconium cyclosilicate hydrate 10 g powder for oral suspension sachet.
-
Prescription medicine registrationActive ingredients: osimertinib mesilate.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Prescription medicine registrationActive ingredients: osimertinib mesilate.
-
Australian public assessment report (AusPar)Lokelma (sodium zirconium cyclosilicate hydrate) was approved for the treatment of hyperkalaemia (high potassium levels in blood) in adult patients.
-
Australian public assessment report (AusPar)Enhertu (trastuzumab deruxtecan) was approved to treat adult patients with unresectable or metastatic HER2-low breast cancer.
-
Australian public assessment report (AusPar)Sidapvia (dapagliflozin+sitagliptin), a new drug combination, has been approved to treat type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control.
-
-
Australian public assessment report (AusPar)Lynparza (olaparib) has been approved for the treatment of BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer.